Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab,...